ライフサイエンスコーパス: vicriviroc

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 tropism changes or reduced susceptibility to vicriviroc.

2 Among 90 recipients of vicriviroc, a significantly (P< .001) greater mean reduc

3 rn associated with reduced susceptibility to vicriviroc, although numerous changes were observed in t

4 Vicriviroc, an investigational CCR5 inhibitor, demonstra

5 ve to most other CCR5 antagonists, including vicriviroc and aplaviroc.

6 nancies occurred in 6 subjects randomized to vicriviroc and in 2 to placebo.

7 nces in this ratio were found for maraviroc, vicriviroc, aplaviroc, Sch-C, TAK652, and TAK779.

8 Five clinical candidates: maraviroc, vicriviroc, aplaviroc, TAK-779, and TAK-220 were used to

9 Vicriviroc at 5, 10, or 15 mg or placebo was added to th

10 -1-infected, treatment-experienced patients, vicriviroc demonstrated potent virologic suppression thr

11 The CCR5 antagonists maraviroc or vicriviroc, developed to block CCR5 HIV coreceptor funct

12 y inhibitors maraviroc, AD101, CMPD 167, and vicriviroc dramatically increases receptor stability.

13 ses that exhibited reduced susceptibility to vicriviroc, envelope clones were phenotypically and geno

14 evel (log(10) copies/mL) were greater in the vicriviroc groups (-0.87 and -1.51 [5 mg], -1.15 and -1.

15 Further development of vicriviroc in treatment-experienced patients is warrante

16 a double-blind, randomized phase 2 study of vicriviroc in treatment-experienced, human immunodeficie

17 Vicriviroc is a C-C motif chemokine receptor 5 (CCR5) an

18 Reduced susceptibility to vicriviroc, manifested as decreases in the maximum perce

19 ximal responses for aplaviroc, maraviroc and vicriviroc suggests that these modulators have minimal e

20 The relationship of vicriviroc to malignancy is uncertain.

21 Twenty-six vicriviroc-treated subjects experienced virological fail

22 rom a phase IIb study of the CCR5 antagonist vicriviroc (VCV) and identified one individual with HIV-

23 Vicriviroc (VCV) is a CCR5 antagonist with nanomolar act

24 Vicriviroc (VCV) is a chemokine (C-C motif) receptor 5 (

25 Vicriviroc (VCV) is a small-molecule CCR5 coreceptor ant

26 ected individual who developed resistance to vicriviroc (VCV), an investigational CCR5 antagonist, du

27 antagonist resistance during treatment with vicriviroc (VCV), an investigational small-molecule CCR5

28 Small-molecule CCR5 inhibitors such as vicriviroc (VVC) and maraviroc (MVC) are allosteric modu

29 85.16, to the small molecule CCR5 inhibitor, vicriviroc (VVC).

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。